{{Rsnum
|rsid=486060
|Chromosome=6
|position=53591884
|Orientation=plus
|GMAF=0.1304
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 6.2 | 93.8
| HCB | 1.5 | 28.5 | 70.1
| JPT | 6.2 | 35.4 | 58.4
| YRI | 6.1 | 36.7 | 57.1
| ASW | 1.8 | 36.8 | 61.4
| CHB | 1.5 | 28.5 | 70.1
| CHD | 4.6 | 31.2 | 64.2
| GIH | 5.0 | 41.6 | 53.5
| LWK | 4.6 | 34.3 | 61.1
| MEX | 0.0 | 22.8 | 77.2
| MKK | 2.6 | 29.2 | 68.2
| TSI | 0.0 | 5.0 | 95.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs486060
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.09, combined P value= 2.45E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470217
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs486060
|overall_frequency_n=21
|overall_frequency_d=128
|overall_frequency=0.164062
|n_genomes=16
|n_genomes_annotated=0
|n_haplomes=19
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}